Johnson & Johnson (JNJ) Q3 FY26 earnings call

Johnson & Johnson delivered a strong third quarter, driven by robust performance in its Innovative Medicine segment, particularly in Oncology and Immunology, which offset underperformance in MedTech. The company raised its full-year operational sales guidance, expecting to surpass $100 billion in annual revenue for the first time. Management remains confident in achieving double-digit growth by the end of the decade, supported by new product launches and pipeline catalysts, while actively addressing MedTech headwinds.